Gentian Diagnostics AS (OSL:GENT) Total Liabilities : kr35.6 Mil (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Gentian Diagnostics AS Total Liabilities?

Gentian Diagnostics AS's Total Liabilities for the quarter that ended in Dec. 2024 was kr35.6 Mil.

Gentian Diagnostics AS's quarterly Total Liabilities declined from Jun. 2024 (kr29.49 Mil) to Sep. 2024 (kr27.65 Mil) but then increased from Sep. 2024 (kr27.65 Mil) to Dec. 2024 (kr35.61 Mil).

Gentian Diagnostics AS's annual Total Liabilities increased from Dec. 2022 (kr33.62 Mil) to Dec. 2023 (kr34.40 Mil) and increased from Dec. 2023 (kr34.40 Mil) to Dec. 2024 (kr35.61 Mil).

Gentian Diagnostics AS Total Liabilities Historical Data

The historical data trend for Gentian Diagnostics AS's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gentian Diagnostics AS Total Liabilities Chart

Gentian Diagnostics AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

40.69

37.02

33.62

34.40

35.61

Gentian Diagnostics AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															34.40	35.17	29.49	27.65	35.61

Gentian Diagnostics AS Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Gentian Diagnostics AS's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	30.108	+	(5.507	+	-0.001000000000003
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	35.6

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	229.664	-	194.05
	=	35.6

Gentian Diagnostics AS's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	30.108	+	(5.507	+	-0.001000000000003
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	35.6

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	229.664	-	194.05
	=	35.6

Gentian Diagnostics AS Total Liabilities Related Terms

Thank you for viewing the detailed overview of Gentian Diagnostics AS's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Gentian Diagnostics AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gentian Diagnostics AS (OSL:GENT) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bjornasveien 5, Moss, NOR, 1596

Website

https://www.gentian.com

Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in-vitro diagnostic reagents (IVD) for use in medical diagnostics and research. Its portfolio and pipeline of reagents span areas of inflammations, severe infections, kidney diseases, heart failures, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP among others. Geographically, it generates a majority of its revenue from Europe followed by Asia and the United States of America.